BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 31680297)

  • 21. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
    Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
    Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
    Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spliceosomal factor mutations and mis-splicing in MDS.
    Hershberger CE; Daniels NJ; Padgett RA
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
    Nagehan P; Sabbir M; Song J; Mohammad H
    J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.
    Shiozawa Y; Malcovati L; Gallì A; Sato-Otsubo A; Kataoka K; Sato Y; Watatani Y; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Makishima H; Shiraishi Y; Chiba K; Hellström-Lindberg E; Miyano S; Ogawa S; Cazzola M
    Nat Commun; 2018 Sep; 9(1):3649. PubMed ID: 30194306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
    Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
    Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.
    Zhang J; Ali AM; Lieu YK; Liu Z; Gao J; Rabadan R; Raza A; Mukherjee S; Manley JL
    Mol Cell; 2019 Oct; 76(1):82-95.e7. PubMed ID: 31474574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
    Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
    Elife; 2022 Aug; 11():. PubMed ID: 36040792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
    Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
    Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
    Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
    Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
    Jenkins JL; Kielkopf CL
    Trends Genet; 2017 May; 33(5):336-348. PubMed ID: 28372848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Role of Aberrant Splicing in Pathogenesis of Myelodysplastic Syndromes-Review].
    Li L; Xiao ZJ; Sun XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):617-621. PubMed ID: 28446323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal.
    Xu JJ; Smeets MF; Tan SY; Wall M; Purton LE; Walkley CR
    Exp Hematol; 2019 Feb; 70():10-23. PubMed ID: 30408513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.
    Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS
    Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complex landscape of alternative splicing in myeloid neoplasms.
    Hershberger CE; Moyer DC; Adema V; Kerr CM; Walter W; Hutter S; Meggendorfer M; Baer C; Kern W; Nadarajah N; Twardziok S; Sekeres MA; Haferlach C; Haferlach T; Maciejewski JP; Padgett RA
    Leukemia; 2021 Apr; 35(4):1108-1120. PubMed ID: 32753690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
    Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
    Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
    Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.